Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima
Abstract
was >90% against MICs of ≤4 μg/ml for all infection sites and renal function groups except for BSI/sepsis patients with normal renal function (85%). These study results support adequate plasma exposure can be achieved at the cefiderocol recommended dosing regimen for the infected patients, including the patients with augmented renal function, ventilation, and/or severe illness.
Topics & Concepts
CephalosporinPharmacokineticsSepsisPneumoniaMedicinePharmacodynamicsAntibioticsUrinary systemPharmacologyCarbapenemDosingPopulationNephrotoxicityIntensive care medicineInternal medicineMicrobiologyBiologyToxicityEnvironmental healthAntibiotics Pharmacokinetics and EfficacyAntibiotic Resistance in BacteriaAntibiotic Use and Resistance